New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
12:20 EDTISIS, TPX, FTNT, FIO, CRUSStocks with increasing option volume; ISIS TPX FTNT FIO CRUS
News For ISIS;TPX;FTNT;FIO;CRUS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
07:37 EDTISISIsis Pharmaceuticals management to meet with Deutsche Bank
Subscribe for More Information
September 29, 2014
08:25 EDTISISIsis Pharmaceuticals management to meet with Deutsche Bank
Meetings to be held in Baltimore/Philadelphia on September 29 hosted by Deutsche Bank.
September 26, 2014
10:01 EDTISISOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:20 EDTISISIsis Pharmaceuticals assumed with a Market Perform at Leerink
Subscribe for More Information
06:39 EDTFTNTMost connected devices have security flaw, NY Times says
Subscribe for More Information
September 25, 2014
08:59 EDTISISSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
September 24, 2014
06:42 EDTTPXMore e-commerce start-ups undercutting established firms, NY Times says
Subscribe for More Information
September 22, 2014
15:14 EDTISISIsis Pharmaceuticals management to meet with JPMorgan
Meeting to be held in Los Angeles on September 22 hosted by JPMorgan.
September 19, 2014
08:11 EDTCRUSTriQuint chip among those in iPhone 6 Plus, iFixit reports
Subscribe for More Information
08:03 EDTCRUSInvenSense, NXP, RF Micro chips included in iPhone 6, iFixit reports
Subscribe for More Information
07:34 EDTTPXTempur Sealy price target raised to $75 from $64 at Piper Jaffray
Piper Jaffray raised its price target for Tempur Sealy shares to $75 after meeting with management and reiterates an Overweight rating on the stock. Piper believes Tempur hit an inflection point in Q3, with the company seeing an acceleration in sales and earnings growth.
07:31 EDTTPXTempur, Mattress Firm weakness would be buying opportunity, says Piper
Subscribe for More Information
September 17, 2014
07:29 EDTISISIsis Pharmaceuticals earns $4M from Achaogen for Phase 3 study of plazomicin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use